PI: Stephen D. Nimer, MD ABSTRACT The leukemogenic AML1-ETO fusion protein, generated by the t(8;21), is the most common fusion protein in acute myeloid leukemia (AML). It contains the N-terminus of AML1/RUNX1, a transcription factor (TF) required for the development of definitive hematopoiesis in mice, and nearly the entire ETO protein, generally thought to function by recruiting co-repressor complexes, thereby turning AML1-ETO into a repressor of transcription1. We have previously identified a variety of genes whose expression is increased by AML1-ETO, but the mechanisms underlying this effect are not known. We have now determined that AML1-ETO binds the """"""""histone"""""""" lysine acetyltransferase p300 via its NHR1 domain (aa 245-430), which leads to its acetylation at lysine 43 (K43) and lysine 24 (K24). Deletion of the NHR1 domain eliminates the ability of AML1-ETO to activate gene expression but not its ability to function as a repressor. Furthermore, the NHR1 domain is required for the self-renewal promoting properties of AML1- EO, but not its ability to block differentiation. Based on the ability of AML1-ETO to recruit p300, we have determined that acetylation at K43, is absolutely essential for its leukemia and self- renewal promoting properties in both mouse and human AML models. This suggests several potential therapeutic strategies that could target this subtype of AML, including the use of p300 inhibitors, or inhibitors that block the binding of bromodomain-containing proteins which can bind to acetyl-K43 in AML1-ETO. To define the importance of specific protein-protein interactions involving AML1-ETO in leukemogenesis and the clinical applicability of targeting its activation, we propose the following specific aims:
Aim1 : Define the effect of p300 inhibitors on AML1-ETO driven AML using mouse models, cord blood derived human CD34+ cell models, and primary t(8;21)+ AML patient samples.
Aim 2 : Determine the role that transcriptional regulatory proteins that bind to K43 acetylated AML1- ETO (e.g. TAF7 or TAF 250) play in AML1-ETO driven leukemogenesis using RNA interference approaches.
Aim 3 : Determine whether blocking the binding of p300 or the critical transcriptional regulatory proteins that bind K43 acetylated AML1-ETO will have therapeutic efficacy against AML1-ETO driven AML. By defining the mechanisms required for the self-renewal of leukemia stem cells and for the expression of key genes that promote leukemia cell growth, we will devise new """"""""targeted"""""""" therapeutic strategies for this dreadful disease.

Public Health Relevance

PI: Stephen D. Nimer, MD Relevance The successful targeting of leukemia stem (or initiating) cell self-renewal can hopefully improve clinical outcomes for patients with AML. We have made a key insight into the pathogenesis of AML1-ETO driven leukemia, and will hopefully develop novel ways of blocking this process.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA166835-03
Application #
8701254
Study Section
Special Emphasis Panel (ZRG1-BMCT-C (09))
Program Officer
Mufson, R Allan
Project Start
2012-09-17
Project End
2017-07-31
Budget Start
2014-08-01
Budget End
2015-07-31
Support Year
3
Fiscal Year
2014
Total Cost
$307,951
Indirect Cost
$106,676
Name
University of Miami School of Medicine
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
052780918
City
Coral Gables
State
FL
Country
United States
Zip Code
33146
Luo, Huacheng; Wang, Fei; Zha, Jie et al. (2018) CTCF boundary remodels chromatin domain and drives aberrant HOX gene transcription in acute myeloid leukemia. Blood 132:837-848
Guo, Ying; Yang, Hui; Chen, Shi et al. (2018) Reduced BAP1 activity prevents ASXL1 truncation-driven myeloid malignancy in vivo. Leukemia 32:1834-1837
Yang, Hui; Kurtenbach, Stefan; Guo, Ying et al. (2018) Gain of function of ASXL1 truncating protein in the pathogenesis of myeloid malignancies. Blood 131:328-341
Hamard, Pierre-Jacques; Santiago, Gabriel E; Liu, Fan et al. (2018) PRMT5 Regulates DNA Repair by Controlling the Alternative Splicing of Histone-Modifying Enzymes. Cell Rep 24:2643-2657
Greenblatt, Sarah M; Man, Na; Hamard, Pierre-Jacques et al. (2018) CARM1 Is Essential for Myeloid Leukemogenesis but Dispensable for Normal Hematopoiesis. Cancer Cell 33:1111-1127.e5
Li, Zhaomin; Zhang, Peng; Yan, Aimin et al. (2017) ASXL1 interacts with the cohesin complex to maintain chromatid separation and gene expression for normal hematopoiesis. Sci Adv 3:e1601602
Li, Jianping; He, Fuhong; Zhang, Peng et al. (2017) Loss of Asxl2 leads to myeloid malignancies in mice. Nat Commun 8:15456
Huber, Ferdinand M; Greenblatt, Sarah M; Davenport, Andrew M et al. (2017) Histone-binding of DPF2 mediates its repressive role in myeloid differentiation. Proc Natl Acad Sci U S A 114:6016-6021
Man, Na; Tan, Yurong; Sun, Xiao-Jian et al. (2017) Caspase-3 controls AML1-ETO-driven leukemogenesis via autophagy modulation in a ULK1-dependent manner. Blood 129:2782-2792
Cheng, G; Liu, F; Asai, T et al. (2017) Loss of p300 accelerates MDS-associated leukemogenesis. Leukemia 31:1382-1390

Showing the most recent 10 out of 30 publications